S Hendrix
Overview
Explore the profile of S Hendrix including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen T, Hutchison R, Rubel C, Murphy J, Xie J, Montenigro P, et al.
J Prev Alzheimers Dis
. 2024 Oct;
11(5):1228-1240.
PMID: 39350368
Changes in biomarker levels of Alzheimer's disease (AD) reflect underlying pathophysiological changes in the brain and can provide evidence of direct and downstream treatment effects linked to disease modification. Recent...
2.
Dickson S, Haaland B, Mallinckrodt C, Dubois B, OKeefe P, Morgan M, et al.
J Prev Alzheimers Dis
. 2024 May;
11(3):529-536.
PMID: 38706269
Background: Disease modifying therapies (DMTs) may be most beneficial in early disease, when progression is slow and changes small, with clinical relevance difficult to interpret. Objectives: Time component tests (TCTs)...
3.
Dickson S, Wessels A, Dowsett S, Mallinckrodt C, Sparks J, Chatterjee S, et al.
J Prev Alzheimers Dis
. 2023 Jun;
10(3):595-599.
PMID: 37357301
In Alzheimer's disease (AD) clinical trials, disease-modifying therapies are expected to slow the rate of disease progression. Treatment effects are evaluated using a validated clinical scale as the difference between...
4.
Cummings J, Apostolova L, Rabinovici G, Atri A, Aisen P, Greenberg S, et al.
J Prev Alzheimers Dis
. 2023 Jun;
10(3):362-377.
PMID: 37357276
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild...
5.
Kettunen H, Bento M, Lewis E, Remington S, Matthews A, Hendrix S, et al.
Br Poult Sci
. 2022 Aug;
63(6):847-856.
PMID: 35946320
1. The following study was conducted to evaluate the tolerability of tall oil fatty acid (TOFA) to broiler chickens, at three graded levels as a nutritional additive in complete feed.2....
6.
Cummings J, Rabinovici G, Atri A, Aisen P, Apostolova L, Hendrix S, et al.
J Prev Alzheimers Dis
. 2022 May;
9(2):221-230.
PMID: 35542993
Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab Appropriate Use Recommendations (AURs)...
7.
Bateman R, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, et al.
J Prev Alzheimers Dis
. 2019 May;
6(3):169-173.
PMID: 31062827
There is an urgent need to develop reliable and sensitive blood-based biomarkers of Alzheimer's disease (AD) that can be used for screening and to increase the efficiency of clinical trials....
8.
Sano M, Soto M, Carrillo M, Cummings J, Hendrix S, Mintzer J, et al.
J Prev Alzheimers Dis
. 2018 Apr;
5(2):98-102.
PMID: 29616702
For the second time in the past 3 years, the EU-US CTAD Task Force addressed challenges related to designing clinical trials for agitation in dementia, which is one of the...
9.
Schneeberger A, Hendrix S, Mandler M, Ellison N, Burger V, Brunner M, et al.
J Prev Alzheimers Dis
. 2017 Dec;
2(2):103-114.
PMID: 29231230
Objectives: The primary objective of this clinical trial was to assess the clinical activity of various doses and formulations of AFFITOPE® AD02 following its repeated s.c. administration to patients with...
10.
Hendrix S, Ellison N, Stanworth S, Otcheretko V, Tariot P
J Prev Alzheimers Dis
. 2017 Dec;
2(3):165-171.
PMID: 29226942
Background: Several randomized trials have demonstrated superiority of memantine-cholinesterase inhibitor combination therapy in patients with moderate to severe Alzheimer's disease, yet a recent publication reported no additional benefit of add-on...